Pertinently, the MSTN neutralizing antibody LY2495655 did not improve survival in a Phase 2 trial of 125 patients with stage 2–4 pancreatic cancer, and indeed treatment trended poorer survival [55]. Here, MSTN is linked to pancreatic neoplasm.